Literature DB >> 17597811

Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.

C G Mullighan1, A Kennedy, X Zhou, I Radtke, L A Phillips, S A Shurtleff, J R Downing.   

Abstract

Somatic mutations in nucleophosmin (NPM1) occur in approximately 35% of adult acute myeloid leukemia (AML). To assess the frequency of NPM1 mutations in pediatric AML, we sequenced NPM1 in the diagnostic blasts from 93 pediatric AML patients. Six cases harbored NPM1 mutations, with each case lacking common cytogenetic abnormalities. To explore the phenotype of the AMLs with NPM1 mutations, gene expression profiles were obtained using Affymetrix U133A microarrays. NPM1 mutations were associated with increased expression of multiple homeobox genes including HOXA9, A10, B2, B6 and MEIS1. As dysregulated homeobox gene expression is also a feature of MLL-rearranged leukemia, the gene expression signatures of NPM1-mutated and MLL-rearranged leukemias were compared. Significant differences were identified between these leukemia subtypes including the expression of different HOX genes, with NPM1-mutated AML showing higher levels of expression of HOXB2, B3, B6 and D4. These results confirm recent reports of perturbed HOX expression in NPM1-mutated adult AML, and provide the first evidence that the NPM1-mutated signature is distinct from MLL-rearranged AML. These findings suggest that mutated NPM1 leads to dysregulated HOX expression via a different mechanism than MLL rearrangement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597811     DOI: 10.1038/sj.leu.2404808

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  73 in total

1.  The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development.

Authors:  Carol F Webb; James Bryant; Melissa Popowski; Laura Allred; Dongkoon Kim; June Harriss; Christian Schmidt; Cathrine A Miner; Kira Rose; Hwei-Ling Cheng; Courtney Griffin; Philip W Tucker
Journal:  Mol Cell Biol       Date:  2011-01-03       Impact factor: 4.272

2.  Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.

Authors:  Chinavenmeni S Velu; Aditya Chaubey; James D Phelan; Shane R Horman; Mark Wunderlich; Monica L Guzman; Anil G Jegga; Nancy J Zeleznik-Le; Jianjun Chen; James C Mulloy; Jose A Cancelas; Craig T Jordan; Bruce J Aronow; Guido Marcucci; Balkrishen Bhat; Brian Gebelein; H Leighton Grimes
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

3.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

4.  Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.

Authors:  Brian V Balgobind; Marry M Van den Heuvel-Eibrink; Renee X De Menezes; Dirk Reinhardt; Iris H I M Hollink; Susan T J C M Arentsen-Peters; Elisabeth R van Wering; Gertjan J L Kaspers; Jacqueline Cloos; Evelien S J M de Bont; Jean-Michel Cayuela; Andre Baruchel; Claus Meyer; Rolf Marschalek; Jan Trka; Jan Stary; H Berna Beverloo; Rob Pieters; C Michel Zwaan; Monique L den Boer
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

5.  MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing.

Authors:  Corina Schneidawind; Johan Jeong; Dominik Schneidawind; In-Suk Kim; Jesús Duque-Afonso; Stephen Hon Kit Wong; Masayuki Iwasaki; Erin H Breese; James L Zehnder; Matthew Porteus; Michael L Cleary
Journal:  Blood Adv       Date:  2018-04-24

Review 6.  Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.

Authors:  Rachel Rau; Patrick Brown
Journal:  Hematol Oncol       Date:  2009-12       Impact factor: 5.271

7.  C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis.

Authors:  Cailin Collins; Jingya Wang; Hongzhi Miao; Joel Bronstein; Humaira Nawer; Tao Xu; Maria Figueroa; Andrew G Muntean; Jay L Hess
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

Review 8.  Therapeutic implications of menin inhibition in acute leukemias.

Authors:  Ghayas C Issa; Farhad Ravandi; Courtney D DiNardo; Elias Jabbour; Hagop M Kantarjian; Michael Andreeff
Journal:  Leukemia       Date:  2021-06-15       Impact factor: 11.528

9.  Integrative meta-analysis of differential gene expression in acute myeloid leukemia.

Authors:  Brady G Miller; John A Stamatoyannopoulos
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

10.  Quantitative comparison of microarray experiments with published leukemia related gene expression signatures.

Authors:  Hans-Ulrich Klein; Christian Ruckert; Alexander Kohlmann; Lars Bullinger; Christian Thiede; Torsten Haferlach; Martin Dugas
Journal:  BMC Bioinformatics       Date:  2009-12-15       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.